You are currently viewing Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th


Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
Representation image: This image is an artistic interpretation related to the article theme.

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

* **Rapid Onset of Action:** Anaphylm™ delivers epinephrine quickly and efficiently, with a peak effect within 5 minutes. This rapid onset is crucial for treating life-threatening allergic reactions. * **Sublingual Administration:** Unlike traditional injections, Anaphylm™ can be administered sublingually, meaning it dissolves under the tongue.

Aquestive’s mission is to improve patient lives through innovative science and delivery technologies. This mission is reflected in their commitment to developing and commercializing oral medications that address unmet medical needs. They focus on complex molecules that are difficult to administer through traditional methods, such as injections or intravenous infusions. The company’s core competencies lie in the development of oral drug delivery systems, including:
* **Microencapsulation:** Encapsulating active ingredients in tiny particles to protect them from degradation and improve absorption.

Leave a Reply